SecBot SecBot

SABS

SAB Biotherapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001833214 Biotech & Drug Discovery
$3.00 +0.04 (+1.35%)
Nov 16 4:00 PM ET · prev $2.96
Market cap
$277.5M
Micro cap
Median target
$12.00
+300% · range $6.00–16.00
1 year
−14.3%
from $3.50 · Nov 17
30 days
+15.4%
from $2.60
52-week range
$2.49–4.59
−35% from high · low Oct 14
Avg volume 20D
668.9K
Nov 12 spike 2.11M
Short interest
5.03M
≈5.6% of shares · +4.7%
Days to cover
8.3
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 19 added (0 new), 6 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.272 → −$0.244 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +4.7% to 5.03M shares. 8.3 days to cover, ≈5.6% of shares.

  • TrendRANGE

    3% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPADD737,138$2.3M
UBS Group AGADD530,587$1.7M
VANGUARD PORTFOLIO MANAGEMENT LLCADD372,890$1.2M
ALPS ADVISORS INCADD119,688$379.4K
AMERICAN CENTURY COMPANIES INCADD109,243$346.3K
MORGAN STANLEYDOUBLED90,102$285.6K
JPMORGAN CHASE & COADD31,565$101.6K
Vanguard Global Advisers, LLCADD23,210$73.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jun 2026
12-month targets · 11 analysts

Price is below the lowest target. Median implies +300%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Jun 24, 2026Barclays
INITIATE
INITIATEOverweight
Jun 17, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Jun 15, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Jun 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 22, 2026Citigroup
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 17, 2026
Kropotova Alexandra
CHIEF MEDICAL OFFICER
Sep 17, 2026
TAX W/H473 sh
Jun 25, 2026
Kropotova Alexandra
CHIEF MEDICAL OFFICER
Jun 25, 2026
TAX W/H988 sh
Mar 24, 2026
Kropotova Alexandra
CHIEF MEDICAL OFFICER
Mar 24, 2026
TAX W/H988 sh
Feb 3, 2026
Sullivan Eddie Joe
PRESIDENT
Feb 3, 2026
AWARD3,000,000 sh
Feb 3, 2026
Bausch Christoph Lawrence
CHIEF OPERATING OFFICER
Feb 3, 2026
AWARD1,800,000 sh
Feb 3, 2026
Kropotova Alexandra
CHIEF MEDICAL OFFICER
Feb 3, 2026
AWARD2,400,000 sh
Feb 3, 2026
To Lucy
See Remarks
Feb 3, 2026
AWARD2,400,000 sh
Feb 3, 2026
Reich Samuel J
CEO
Feb 3, 2026
AWARD4,800,000 sh

Earnings setup

Estimates
−$0.24
EPS estimate, this quarter
+10%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.24-$0.31–-$0.19+10.0%$0.00
Next Q-$0.25-$0.32–-$0.21-21.3%$0.00
Current FY-$1.13-$1.16–-$1.06+3.2%$0.00
Next FY-$0.94-$1.20–-$0.60+1.3%$62.5K

Short side

FINRA· Oct 30, 2026
5,026,127
shares short
+4.7%
vs prior settlement
8.3
days to cover
≈5.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 5, 2026 Earnings
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric
Oct 13, 2026 Press
SAB Biotherapeutics announced FDA Fast Track designation for its lead candidate SAB-142, a disease-modifying…
Impact 5/10
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
737,138 shares ($2.3M)
Sep 30, 2026 Inst.
UBS Group AG · ADD
530,587 shares ($1.7M)
Sep 17, 2026 Insider
Kropotova Alexandra surrendered for taxes 473 shares
CHIEF MEDICAL OFFICER
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

9 filings · 6 press releases · 2 bullish · 2 bearish · 5 neutral
All SABS filing & press-release reports (15)